AKT1 and glioblastoma: Moreover, treatment of the AKT inhibitor MK-2206, or the DNA-PKcs inhibitor KU-57788, could abrogate pericyte CM-activated DDR upon TMZ treatment, as shown by reduced phosphorylation of DNA-PKcs and increased γ-H2AX in GBM cells treated with each inhibitor (Fig. 5k; Supplementary information, Fig. S5k).